Trial Profile
The IAI-OCTA Study or; Microvascular Structure and Morphology of Neovascular Membranes in Age Related Macular Degeneration (AMD) After Intravitreal Aflibercept Injection (IAI) Therapy Using OCT-Angiography Analysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms IAI-OCTA
- 08 Jul 2021 Status changed from active, no longer recruiting to completed.
- 07 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Dec 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.